What is AB-106, Itraconazole used for?

AB-106, Itraconazole is indicated for Fungal infections.

Who makes AB-106, Itraconazole?

AB-106, Itraconazole is developed by Nuvation Bio Inc..

What development phase is AB-106, Itraconazole in?

AB-106, Itraconazole is in Phase 1.

What are the side effects of AB-106, Itraconazole?

Common side effects include Hepatotoxicity, QT interval prolongation.

Last reviewed 2026-04-23 · How we verify

AB-106, Itraconazole

Nuvation Bio Inc. · Phase 1 active Small molecule

Inhibits fungal cytochrome P450 14α-demethylase

Inhibits fungal cytochrome P450 14α-demethylase Used for Fungal infections.

At a glance

Generic name	AB-106, Itraconazole
Sponsor	Nuvation Bio Inc.
Drug class	Azole antifungal
Target	Cytochrome P450 14α-demethylase
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 1

Mechanism of action

This inhibition prevents the conversion of lanosterol to ergosterol, an essential component of fungal cell membranes.

Approved indications

Fungal infections

Common side effects

Hepatotoxicity
QT interval prolongation

Key clinical trials

A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AB-106, Itraconazole CI brief — competitive landscape report
AB-106, Itraconazole updates RSS · CI watch RSS
Nuvation Bio Inc. portfolio CI